𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: The SPIRIT FIRST trial

✍ Scribed by Marcus Wiemer; Patrick W. Serruys; Karine Miquel-Hebert; Franz-Josef Neumann; Jan J. Piek; Eberhard Grube; Jürgen Haase; Leif Thuesen; Christian Hamm

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
179 KB
Volume
75
Category
Article
ISSN
1522-1946

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Four-year clinical follow-up of the XIEN
Four-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: The SPIRIT II trial
✍ Scot Garg; Patrick W. Serruys; Karine Miquel-Hebert; on behalf of the SPIRIT II 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 219 KB 👁 1 views

## Abstract This report describes the 4‐year clinical outcomes of the SPIRIT II study, which randomized 300 patients to treatment with the XIENCE V everolimus‐eluting stent (EES), or the TAXUS paclitaxel‐eluting stent. At 4‐year clinical follow‐up, which was available in 256 (85.3%) patients, treat